|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1979
|
|
gptkbp:atccode
|
A02 BA01
|
|
gptkbp:available_on
|
gptkb:tablet
gptkb:Sugar
injection
|
|
gptkbp:brand
|
gptkb:Tagamet
|
|
gptkbp:casnumber
|
51481-61-9
|
|
gptkbp:chemical_formula
|
C10 H16 N6 S
|
|
gptkbp:clinical_trial
|
Phase IV
|
|
gptkbp:clinical_use
|
maintenance therapy for duodenal ulcers
short-term treatment of active duodenal ulcers
treatment of benign gastric ulcers
treatment of erosive esophagitis
|
|
gptkbp:contraindication
|
liver disease
renal impairment
|
|
gptkbp:discovered_by
|
gptkb:Smith_Kline_&_French_Laboratories
|
|
gptkbp:dosage_form
|
300 mg three times a day
400 mg twice a day
600 mg once a day
800 mg at bedtime
|
|
gptkbp:duration
|
up to 8 weeks
long-term use possible
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cimetidine
|
|
gptkbp:interacts_with
|
gptkb:phenytoin
gptkb:theophylline
gptkb:warfarin
benzodiazepines
|
|
gptkbp:invention
|
gptkb:1997
|
|
gptkbp:marketed_as
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:mechanism_of_action
|
H2 receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:previous_name
|
yes
|
|
gptkbp:route_of_administration
|
oral
intravenous
|
|
gptkbp:safety
|
Category B
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
confusion
diarrhea
rash
thrombocytopenia
gynecomastia
elevated liver enzymes
impotence
|
|
gptkbp:used_for
|
treating gastroesophageal reflux disease (GERD)
preventing stomach ulcers
treating Zollinger-Ellison syndrome
treating ulcers
|
|
gptkbp:bfsParent
|
gptkb:James_W._Black
gptkb:theophylline
gptkb:Fortamet
|
|
gptkbp:bfsLayer
|
6
|